The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer
Official Title: An Open-label, Single-arm, Multicenter, Phase Ib Clinical Trial to Evaluate the Efficacy and Safety of CT041 Autologous CAR T Cell Injection After Adjuvant Chemotherapy in Subjects With Pancreatic Cancer
Study ID: NCT05911217
Brief Summary: An open-label, single-arm, multicenter, Phase Ib clinical trial to evaluate the efficacy and safety of CT041 Autologous CAR T Cell Injection after adjuvant chemotherapy in subjects with pancreatic cancer.
Detailed Description: This study is an open, multicenter, Phase Ib clinical trial evaluating chimeric antigen receptor-modified autologous T cells targeting Claudin18.2 (CLDN18.2) (CT041 autologous CAR T) in subjects with CLDN18.2 expression-positive pancreatic cancer who has undergone adjuvant chemotherapy. The aim of this study is to evaluate the efficacy, safety of CT041 treatment.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Beijing Cancer Hospital, Beijing, Beijing, China
Henan Cancer Hospital, Zhengzhou, Henan, China
Union Hospital, Tongji Medical College, Hua zhong University of Science and Technology, Wuhan, Hubei, China
Hunan Provincial People's Hospital, Changsha, Hunan, China
Ruijin Hospital, affiliated to Shanghai Jiaotong University, school of medicine, Shanghai, Shanghai, China
Fudan University Shanghai Cancer Hospital, Shanghai, Shanghai, China
The First Affiliated Hospital of Xi'an Jiaotong University, Xian, Shanxi, China
Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China
Name: Xianjun Yu, Ph.D
Affiliation: Fudan University
Role: PRINCIPAL_INVESTIGATOR